FIELD: biotechnology.
SUBSTANCE: present invention relates to a recombinant human myelogenous leukaemia cell line TMDK562-15, which has a surface expression of a membrane-bound form of a chimeric protein consisting of interleukin 15, a combination of CD215 sushi domain signalling molecules and TNFRSF9L (mbIL15sCD215TNFRSF9L).
EFFECT: invention is effective for activation and proliferation of natural killer cells (NK cells) during their co-culturing.
1 cl, 6 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PSCA-CAR-YT CELL LINE HAVING SURFACE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND EXHIBITING CYTOTOXIC ACTIVITY ON PSCA-POSITIVE HUMAN CANCER CELLS | 2018 |
|
RU2712901C1 |
| METHOD FOR LONG-TERM CULTIVATION AND EXPANSION OF NK CELLS WITH HIGH VIABILITY AND FUNCTIONAL ACTIVITY | 2021 |
|
RU2794770C1 |
| FORMATION OF KNOCKOUT PRIMARY AND PROPAGATED HUMAN NK CELLS USING CAS9 RIBONUCLEOPROOTEINS | 2019 |
|
RU2808035C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | 2013 |
|
RU2653761C2 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| METHOD FOR EXPANSION OF HUMAN NK CELLS USING FEEDER CELLS | 2021 |
|
RU2781777C2 |
| UNIVERSAL ANTIGEN PRESENTING CELLS AND THEIR USE | 2019 |
|
RU2809113C2 |
| RECOMBINANT CYTO-CAR-YT-LACT CELL LINE EXHIBITING HIGH CYTOTOXIC ACTIVITY WITH RESPECT TO PSCA-POSITIVE HUMAN CANCER CELLS | 2019 |
|
RU2724431C1 |
| T CELLS RE-TARGETED WITH RESPECT TO CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR, AND METHODS FOR USE THEREOF | 2014 |
|
RU2711114C2 |
